Sanofi (SNY)
43.33
+0.56
(+1.31%)
USD |
NASDAQ |
Sep 14, 16:00
43.33
0.00 (0.00%)
After-Hours: 20:00
Sanofi Enterprise Value : 114.44B for Sept. 14, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 14, 2026 | 114.44B |
| September 11, 2026 | 113.08B |
| September 10, 2026 | 112.95B |
| September 09, 2026 | 113.27B |
| September 08, 2026 | 114.01B |
| September 04, 2026 | 116.65B |
| September 03, 2026 | 116.86B |
| September 02, 2026 | 117.20B |
| September 01, 2026 | 116.96B |
| August 31, 2026 | 116.94B |
| August 28, 2026 | 118.05B |
| August 27, 2026 | 118.10B |
| August 26, 2026 | 119.51B |
| August 25, 2026 | 120.97B |
| August 24, 2026 | 120.17B |
| August 21, 2026 | 120.55B |
| August 20, 2026 | 118.85B |
| August 19, 2026 | 120.51B |
| August 18, 2026 | 118.42B |
| August 17, 2026 | 117.06B |
| August 14, 2026 | 115.38B |
| August 13, 2026 | 115.53B |
| August 12, 2026 | 115.36B |
| August 11, 2026 | 114.99B |
| August 10, 2026 | 114.80B |
| Date | Value |
|---|---|
| August 07, 2026 | 114.75B |
| August 06, 2026 | 113.37B |
| August 05, 2026 | 113.10B |
| August 04, 2026 | 112.86B |
| August 03, 2026 | 113.51B |
| July 31, 2026 | 113.83B |
| July 30, 2026 | 113.37B |
| July 29, 2026 | 118.13B |
| July 28, 2026 | 119.80B |
| July 27, 2026 | 116.06B |
| July 24, 2026 | 114.48B |
| July 23, 2026 | 114.51B |
| July 22, 2026 | 115.55B |
| July 21, 2026 | 115.46B |
| July 20, 2026 | 116.01B |
| July 17, 2026 | 117.67B |
| July 16, 2026 | 116.57B |
| July 15, 2026 | 115.29B |
| July 14, 2026 | 114.07B |
| July 13, 2026 | 116.06B |
| July 10, 2026 | 114.85B |
| July 09, 2026 | 115.82B |
| July 08, 2026 | 113.10B |
| July 07, 2026 | 113.59B |
| July 06, 2026 | 112.69B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 534.29B |
| GSK Plc | 120.70B |
| Eli Lilly & Co. | 1.118T |
| Merck & Co., Inc. | 404.36B |
| Novo Nordisk A/S | 159.93B |
Enterprise Value Related Metrics
| Earnings Yield | 4.48% |
| Operating Earnings Yield | 13.88% |
| Normalized Earnings Yield | 7.928 |